KR101118230B1 - Composition for Anti-influenza virus activity - Google Patents

Abstract

The present invention relates to a plant extract having an anti-influenza virus activity comprising a plant extract selected from at least one selected from banaba, country of origin and oregano, and a method for preventing or treating an influenza virus infection disease by administering the composition.

Influenza Viruses, Antivirals

Description

Composition for anti-influenza virus

The present invention relates to a plant extract having an anti-influenza virus activity comprising a plant extract selected from at least one selected from banaba, country of origin and oregano, and a method for preventing or treating an influenza virus infection disease by administering the composition.

Influenza virus is a virus belonging to the family Orthomyxoviridae and carries the flu.

The flu is the most common disease of the respiratory disease that occurs during the winter season. The main symptom is respiratory disease, but the effect is on the whole body. Acute fever, chills, body aches, loss of food, headache, muscle pain, low back pain symptoms, severe sputum, cough, runny nose, eye redness, etc. may also be accompanied by diarrhea. Influenza is nearly impossible for normal people to live normally for a few days, and the elderly are more serious and can cause death. The virus that causes influenza is influenza virus. Influenza viruses are divided into types A, B, and C. Among them, types A and B are frequently infected with humans. In particular, serotypes of type A viruses are determined by differences in the amino acid sequence of hemagglutinin and neuraminidase proteins. The hemagglutinin (H) of influenza A virus has 16 different subtypes and the neuramididases enzyme (N) has 9 different subtypes.How does the combination of hemagglutinin protein and neuraminidase protein subtypes work? New variants are determined (e.g. H1N1) and new ones may also be present depending on the host's adaptability to the immune system (Yuen KY & Wong SSY., 2005. Hong Kong Med. 11; 189-199). . However, not all 16 subtypes of hemagglutinin protein and 9 subtypes of neuraminidase protein are infected with humans, but 3 subtypes of hemagglutinin protein (H1, 2, 3) and 2 subtypes of neuraminidase protein (N1, 2) It is known to have the ability to infect humans, but H5N1, which is found in birds such as chickens and ducks, can also infect humans (Ligon BL 2005. Semin Pediatr. Infect Dis 16: 325-335). Thus, the frequent incidence of new mutants of influenza virus not only reduces the efficacy of the vaccine, but also prevents the vaccine from coping with new flu viruses that have the potential to infect humans such as avian influenza. Therefore, the development of various treatments to cope with the flu virus is necessary. There are two types of drugs that inhibit the growth of influenza viruses. One is amantadine, an M-ion channel inhibitor developed by Dupont in 1964, used to treat influenza type A virus infections until 1980, resulting in nausea, drowsiness, and chronic insomnia (LongJK., Mossad SB. , Goldman MP. 2000. Cleve Clin J. med. 67: 92-95). Since then, rimantadine has been developed with fewer side effects than amantadine, but rimantadine also has a high incidence of side effects (Jefferson et al., 2004. Cochrane Database Syst. Rev. (3): CD001169). The second type of drug has a function of neuraminidase enzyme inhibitor, and zanamivir and oseamimivir are used to treat influenza virus (Dreitlein WB., Maratos J., Brocavich. 2001. Clin Ther. 23: 327-355). Janamivir is sold under the trademark Relenza by Glaxowelcome Inc. and is inhaled to inhale the powder in the nose. Oseltamivir is sold by Rosh under the name Tamiflu and is sold by amnatadine. It is also used as a mouthwash. Relenza may cause breathing problems, which may make asthma worse and Tamiflu has side effects such as nausea and vomiting (McNicholl and McNicholl. 2001. Ann, Pharmacother. 35 (1): 57-70).

Therefore, it is necessary to develop an antiviral agent that is effective in developing an antiviral agent for influenza virus with low toxicity and side effects.

The search for activity that can suppress influenza virus in natural plants has long been conducted by several researchers (Etkind PR, Krug RM., 1975. J. Virol. 16: 1464-1475; Nagata K., Sakagami H., Harada H., Nonoyama M., Ishihama A., Konno K., 1990. Antiviral Res. 13: 11-21; Harada H., Sakagami H., Nagata K., Oh-Hara T., Kawazoe Y., Ishihama A., Hata N., Terada H., Konno K., 1991.Antiviral Res. 15: 41-49; Nakayama M., Suzuki K., Toda M., Okubo S., Hara Y., Shimamura T., 1993.Antiviral Res. 21: 289-299; Nagai T., Moriguchi R., Suzuki Y., Tomimori T., Yamada H., 1995.Antiviral Res. 26: 11-25; Turan K., Nagata K., Kuru A., 1996. Biochem Biophys Res Commun 225: 22-26; Kobayashi M., Davis SM., Utsunomiya T., Pollard RB., Suzuki F. 1999. Am J Clin med 27: 53-62; Merten OW. , Manuguerra JC., Hannoum C., van der Werf S. 1999. Dev. Biol.Stand. 98: 23-27; Mantani N., Andoh T., Kawamata H., Terasawa K., Ochiai H. Antiviral Res. 44: 193-200; Badmaev V., Nowakow ski M. 2000. Phytother Res. 14: 245-249; Rajbhandari M., Wegner U., Julich M., Schopke T., Mentel R. 2001. J Ethnop-harmacol. 74: 251-255. Mantani N., Imanishi N., Kawamata H., Terasawa K., Ochiai H. 2001. Planta Med. 67: 240-243; Imanishi N., Tiji Y., Katada Y., Maruhashi M., Konosu S., Mantani N., Terasawa K., Ochiai H. 2002. Microbiol Immunol. 46: 491-494; Weiss EI., Houri-Haddad Y., Greenbaum E., Hochman N., Ofda I., Z Mahon-Rones Z. 2005. Antiviral Res. 66: 9-12) Some plants have been reported to have antiviral activity (Kinghorn AD (1994) The discovery of drugs from higher plants.Biotechnology, 26: 81-108 .; Patrick L (1999) Hepatitis C Altern Med Rev., 4 (4): 220-38), has not yet been applied to the treatment of viral infections because plant extracts are not as effective as conventional antiviral agents in epidemiology and review of complementary / alternative medicine treatments.

Accordingly, the present inventors have tried to find a new herbal medicine having excellent antiviral activity against influenza virus, and as a result, by confirming that the composition comprising a banaba, country of origin, oregano extract, or a combination thereof has a proliferation inhibitory effect against influenza virus The present invention has been completed.

One object of the present invention is to provide an anti-influenza virus composition comprising a plant extract selected from at least one of banaba, acid and oregano.

Another object of the present invention is to provide a method for preventing or treating an influenza virus infection disease by administering to a subject a plant extract selected from at least one of banaba, acid and oregano.

In one aspect, the present invention is to provide an anti-influenza virus composition comprising a plant extract selected from at least one of banaba, country of origin and oregano.

For the purposes of the present invention, the virus is an influenza virus, which is the main pathogen of the flu. Influenza virus is a typical virus belonging to the oligomyxoviride family, and has a short-chain negative RNA in its genome and causes respiratory diseases. Influenza viruses are classified into types A, B, and C. Influenza viruses A, B, and C are classified into various subtypes and variants by hemagmaglutinin (HA) and neuraminidase (NA), respectively. Have Influenza virus A and C are known to infect only humans, whereas influenza virus A is known to infect not only humans but also birds (chicken, ducks, geese, turkeys, etc.), pigs and horses.

As used herein, the term “anti-influenza virus activity” refers to the ability to inhibit the production of particles of various subtypes and variants of the influenza virus, more specifically influenza viruses A, B, and C, ie, host cells. It means the ability to effectively inhibit the formation and / or replication of influenza virus in. The composition provided in the present invention has antiviral activity by interfering with the mechanism necessary for viral replication or proliferation.

As used herein, the term "extract" means an active ingredient isolated from a plant, here a substance having antiviral activity against influenza virus, and an organic solvent such as water or alcohol (for example, methanol, ethanol, propanol, butanol, etc.). It is prepared by an extraction process using. Extracts include water or organic solvent extracts, dry powders thereof or any form formulated therewith.

As used herein, the term “Lagerstroemia speciosa Pars” includes all stems, leaves, and flowers of natural, hybrid, or varieties of Banaba, but preferably refers to Banaba leaves. Banaba alcohol extract or water extract can be used as an antiviral composition against influenza virus.

Barnabas has been reported to have a therapeutic effect on diabetic diseases due to its glycemic control ability (Judy WV et al., 2003, J Ethnopharmacol), and Korean Patent Application No. 10-2004-0070652 has a barnabas extract, fenugreek extract and bitter extract It describes a pharmaceutical composition for hypoglycemic containing fermented product obtained by solid fermentation as an active ingredient. However, there have been no examples of antiviral activity, particularly antiviral activity against influenza virus, in Banaba. Banaba water extract of the present invention was found to have a significant inhibition (%) of about 67.10% for influenza virus A, about 53.07% for influenza virus B.

In the present invention, the term “Chrysanthemum boreale Makino.” Includes all stems, leaves, and flowers of natural, hybrid, or mutant country, but preferably means a flower of a country. Water and alcohol extracts from the country of origin can be used as antiviral compositions against influenza virus.

Korean Patent Application No. 10-2000-0006958 describes a method for producing cumambrine A, a hypertension therapeutic agent, and its use as a hypertension therapeutic agent from a country of origin. Korean Patent Application No. 10-2002-0023335 discloses a volatile extract capable of inhibiting the growth of pathogenic Gram-positive bacteria, Gram-negative bacteria and fungi from a country of origin, a method for efficiently extracting and purifying them, and an antibacterial agent containing an active ingredient in the extract and An antifungal composition is described. Antiviral activity in some countries has been reported by some researchers for retroviruses (Lee JS., Kim HJ., Lee YS., 2003. Planta Med. 69: 859-861; Wang Hk. , Xia Y., Yang ZY., Natschke SL., Lee KH. 1998. Adv.Exp. Med. Biol. 439: 191-225; Hu CQ., Chen., Shi Q., Kilkuskie RE., Cheng YC. , Lee KH J Nat Prod. 57: 42-51), there have been no examples of antiviral activity against influenza virus. Methanol extract of the acid country of the present invention was found to have a significant inhibitory ability (%) of about 42.44% for influenza virus A, about 70.32% for influenza virus B.

As used herein, the term “Origanum vulgare L.” includes all stems, leaves, and flowers of natural, hybrid or mutant oregano, but preferably means leaves and stems of oregano. Water and alcohol extracts of oregano can be used as antiviral compositions for influenza virus.

Oregano is mainly used as a fragrance for tea, meat and fish, but there is not much research on biochemical activity. Goun et al. (Goun E., Cunningham., Solodnikov., Krasnykch O., Miles H. 2002. Fitoteripia 73: 692-694) reported that some components have high antithrombin activity in the same plant, and Sokemen et al. (Skemen M , Serkedjieva J., Daferera D., Gulluce M., Polissiou M., Tepe B., Akpulat HA., Sahin F., Sokemen A. 2004. J Agric.Food Chem 52: 3309-3312). The antiviral activity of herpes simplex virus and influenza virus in other origanum acutidens was reported to be very low or very low. The methanol extract of oregano of the present invention was confirmed to have a significant inhibitory activity (%) of about 108% against influenza virus A.

Banaba, acid or oregano extract of the present invention, which has been shown to exhibit an effective inhibitory effect against influenza virus, may be used alone or in combination of two or more components. The blending ratio of the selected components can be adjusted in various ways. In the case of compounding use, the individual components may be combined and extracted, or each component may be extracted and mixed. Preferably, the components may be mixed and then extracted under optimum conditions.

The composition comprising the extract of barnabas, country of origin, oregano, or a combination thereof of the present invention does not increase the efficacy but may include additional ingredients that are commonly used in pharmaceutical compositions to improve odor, taste, vision, and the like. In addition, the composition of the present invention is inorganic, such as vitamins B ₁ , B ₂ , B ₆ , C, E, niacin, carnitine, betaine, folate pantothenic acid, biotin, zinc, iron, calcium, chromium, magnesium, mixtures thereof, and the like. It may further comprise organic additives.

Banaba, acid, or oregano included in the composition of the present invention can be used immediately by extracting with water or an organic solvent, but more preferably, the extract is filtered and the filtrate is dried.

Preferred extract preparation process of the present invention comprises the steps of grinding the medicine; Extracting with a solvent; Filtering the extract; And drying the filtrate.

As the extraction solvent, water or an organic solvent such as alcohol is used, and the active ingredient of the herbal medicine is not destroyed or proceeds under minimized conditions and is extracted by heat extraction or cold extraction. Filtration is a process of removing the suspended solid particles from the extract, it may be used to filter the particles using cotton, nylon, etc., or freezing, centrifugal separation, etc. may be used, but is not limited thereto. Drying the filtrate includes, but is not limited to, lyophilization, vacuum drying, hot air drying, spray drying, reduced pressure drying, spray drying, foam drying, high frequency drying, infrared drying, and the like. Through the drying process, the water content can be reduced to 10% or less, and the process of reducing the water content can be carried out by placing the filtrate in the concentrator before drying. If desired, a process of grinding the final dried extract may be added.

In the case of water extraction, it is preferable to add the components of the composition of the present invention to water and heat at 50 ° C to 70 ° C for 30 minutes to 2 hours. When heating at a high temperature, the time is reduced, but the active ingredient is destroyed and can be lost. When heating at a temperature lower than the temperature, it is important to control the temperature and time properly because the active ingredient of the mixture is not completely extracted. In a specific embodiment of the present invention, the barnabas were extracted by heating at 60 ° C. for 1 hour, the insoluble material was filtered by centrifugation, and the supernatant was lyophilized to prepare a water extract.

When extracted using an organic solvent, methanol, ethanol, isoprotanol, butanol, ethylene, acetone, ether, hexane, chloroform, ethyl acetate, DMF (N, N-dimethylformamide), DMSO (dimethyl sulfoxide), etc. Can be extracted with an organic solvent at room temperature or by heating. Depending on the organic solvent to be extracted, the degree of extraction and loss of the active ingredient of the drug may vary, so select an appropriate organic solvent. Preferably extracted at 20 ℃ to 30 ℃, left for about 12 hours to 48 hours. In a specific embodiment of the present invention, oregano and banaba were extracted by using methanol for 24 hours at room temperature. Subsequently, the insoluble material was filtered using whatman filter paper, and the filtrate was dried under reduced pressure to prepare an organic solvent extract.

The composition of the present invention prepared by the above method can be administered to an individual to treat or prevent an individual infected with influenza virus. Individuals who can administer the compositions of the present invention include all hosts that may be infected with influenza virus, such as humans, birds (chicken, ducks, geese, turkeys, etc.), pigs, horses, and the like. The composition of the present invention can be prepared in various forms such as pharmaceutical compositions, feed compositions, food compositions and the like for the prevention and treatment of influenza virus infection diseases in various individuals.

In a specific embodiment, an anti-influenza virus composition comprising a plant extract selected from at least one of banaba, acid and oregano is provided as a pharmaceutical composition.

The composition of the present invention may comprise a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers can be used as oral administration binders, suspending agents, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, pigments, flavorings, etc., in the case of injections, buffers, preservatives, analgesic Topical agents, solubilizers, isotonic agents, stabilizers and the like can be mixed and used. For topical administration, bases, excipients, lubricants, preservatives and the like can be used. The formulation of the pharmaceutical composition of the present invention may be prepared in various ways by mixing with a pharmaceutically acceptable carrier as described above. For example, in the case of oral administration, it may be prepared in the form of tablets, troches, capsules, elesir, suspensions, syrups, wafers, etc., and in the case of injections, may be prepared in unit dosage ampoules or multiple dosage forms.

In another specific embodiment, an anti-influenza virus composition comprising a plant extract selected from at least one of banaba, acid and oregano is provided as a food (or nutraceutical) composition.

The food composition of the present invention may be formulated in the form of powder, granules, tablets, capsules or drinks by mixing with a suitable carrier and excipients or auxiliary active ingredients in addition to the microorganisms or cultures thereof of the present invention. Suitable carriers, excipients and diluents for use in the formulation of the food compositions of the invention include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, tragacanth rubber, gelatin, calcium silicate , Microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl and propylhydroxybenzoate, talc, magnesium stearate or mineral oil and the like. Lubricants, wetting agents, emulsifiers and suspending agents, preservatives, sweeteners or flavoring agents may be further included for the commercialization of the food composition of the present invention.

In another specific embodiment, an anti-influenza virus composition comprising a plant extract selected from at least one of banaba, country of origin and oregano is provided as a feed composition.

Feed composition of the present invention can be prepared in the form of fermented feed, compound feed, pellet form and silage and the like.

In another aspect, the present invention provides a method for preventing or treating an influenza virus infection disease by administering the composition to a subject suspected of being infected with influenza virus.

In the present invention, the term "influenza virus infection disease" refers to a disease caused by an influenza virus infection, and may exemplify sinusitis, seizure asthma, otitis media, cystic fibrosis, bronchitis, pneumonia, diarrhea, etc. (Pitkaranta and Hayden, Ann. Med. 1998.

As used herein, the term “individual” means all animals including humans already infected with or capable of being infected with influenza virus, and by administering to a subject a composition comprising an extract of the present invention, the disease can be effectively prevented and treated. . For example, the compositions of the present invention can treat humans infected with various influenza virus subtypes or variants of human influenza varus. In addition, the compositions of the present invention can treat humans infected with various influenza virus subtypes or variants of avian influenza virus. It is also possible to treat chickens or pigs infected with various influenza virus subtypes or variants of avian influenza virus. The composition of the present invention can be administered in parallel with existing influenza virus infection disease therapeutics.

As used herein, the term "prevention" means any action that inhibits or delays the influenza virus infection by administration of a composition. As used herein, the term "treatment" means any action that improves or advantageously changes the symptoms caused by influenza virus infection by administration of the composition.

The route of administration of the composition may be administered via any general route as long as it can reach the desired tissue. Intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, intranasal administration, pulmonary administration, rectal administration, but is not limited thereto. The pharmaceutical composition can also be administered by any device in which the active agent can migrate to the target cell.

The composition of the present invention is administered in a pharmaceutically effective amount.

The term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, with an effective dose level of the individual type and severity, age, sex, type of virus infected, drug Activity, sensitivity to drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of drugs, and other factors well known in the medical arts. The compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, and can be easily determined by those skilled in the art.

Hereinafter, preferred examples are provided to aid in understanding the present invention. However, the following examples are merely provided to more easily understand the present invention, and the present invention is not limited by the following examples.

Reference Example  1: Preparation of Water Soluble Extract

Flowers from the country of origin obtained from the redistribution of medicinal plants of Gyeongnam Agricultural Research Institute, oregano leaves and stems harvested from Herb Land Co., Ltd. Made into powder. Each plant powder was added with 10 times the amount of distilled water for each weight, and the mixture was bathed at 60 ° C. for 1 hour, centrifuged at 12000 rpm for 20 minutes to remove insoluble materials, and the supernatant was lyophilized to prepare a water-soluble extract.

Reference Example  2: Preparation of Methanol Extract

Flowers from the country of origin obtained from redistribution of medicinal plants of Gyeongnam Agricultural Research Institute, oregano leaves and stems harvested from Herb Land Co., Ltd., and leaves of banana bar imported directly from foreign countries until dry to 25% of raw vinegar weight, and then ground with a mixer Made with. Each plant powder was added with 10 times the amount of methanol for each weight, and left at room temperature for 24 hours, followed by filtration with whatman filter paper to remove insoluble materials, and the filtered solution was dried using a vacuum extractor to prepare a methanol extract.

Reference Example  3: antiviral agent used as control

Ribavirin, amantadine, acyclovir and azidothymidine, which are currently used as antiviral agents, can be purchased from Sigma to compare the antiviral growth of each plant extract. Lamivudine (lamivudine) was purchased from Glaxowelcome Korea, and diluted in cell culture solution.

Reference Example  4: cultivation of virus

Influenza viruses used in this experiment were influenza virus type A (A / WS / 33) and type B (B / Lee / 40), and each influenza virus was infected by MDCK cells and expanded. MDCK cells were cultured in a 37 ° C. incubator using MEM medium containing 10% of pediatric serum. The medium used for virus growth and antiviral activity was adjusted to 1 ug / ml in serum-free medium. Culture medium was used.

Example  1: virus Inhibitory ability Cytotoxic activity  analysis

In order to measure the virus proliferation inhibitory activity against influenza virus of each plant extract obtained in Reference Example 1, 2 × 10 ⁴ cells of MDCK cells were placed in each well of 96 well plates and incubated for 24 hours. After 24 hours, the culture supernatant of each well was removed and the influenza virus infection solution was added to each well, and each plant extract was administered to each well to a concentration of 50 ug / ml or 0.1, 1, 10, 100 ug / ml. . After 48-72 hours, the virus infection reaction was stopped, and the virus growth inhibition and cytotoxicity of each extract were measured according to Korean Patent Application 10-2004-0111298. The culture supernatant of each well was removed, the cells remaining in the wells were fixed with 100 μl of 70% acetone solution, and 100 μl of sulfohodamine B (SRB) solution was added to each well to stain the cell proteins. After washing and removing the SRB staining agent that is not bound to the cell protein, 100μl of 10mM Tris solution (pH 10.5) is added to each well to dissolve the dye bound to the cells, and the absorbance of each well is measured by EIA reader at 565nm. Was performed. Each treatment group was labeled as virus-free (A), water-only extract (B), virus-only (C), and virus and water-soluble extracts (D). Comparative cell growth rate (%) of the extract and the growth inhibition of the plant extract against the virus was calculated as post-infection cell survival rate (%). The statistics on the results were calculated from the mean and standard deviation of three experimental results under the same conditions.

Existing Antiviral Agents Dosing on  According to the cell Survival rate  analysis

As a result of analyzing the cellular effect on MDCK cells at 50 ug / ml, five kinds of drugs (ribavirin, acyclovir, amantadine, lamividin, azithrothymidine) used as antiviral agents, were analyzed as ribavirin, acyclovir, Cell viability of lamivudine and azithrothymidine was 99.50 ± 4.85%, 95.21 ± 4.35%, 105.84 ± 4.32%, 102.29 ± 7.74%, which did not affect cell proliferation, but amantadine was 48.71 ± 6.41%. It was shown to inhibit the side effects when administered to the cell was confirmed (Table 1).

Conventional Antiviral Agents for Influenza Viruses Antiviral activity  analysis

Analysis of proliferation inhibitory activity against influenza A and B in 50ug / ml doses of 5 drugs (ribavirin, acyclovir, amantadine, lamividin, azithrothymidine) used as antiviral agents Ribavirin showed an excellent inhibitory activity against influenza virus types A and B, 90.54 ± 3.61% and 96.48 ± 1.091%, and amantadine was effective against influenza virus type A only 43.88 ± 4.85% and inhibitory effect against influenza virus type B. Could not exert. This is consistent with what Englund (Englund JA 2002. Semin Pediatr Infect Disease 13: 120-128) described. In addition, acyclovir and azithrothymidine, which are used for the treatment of HIV, showed 0.00 ± 4.05%, 0.00 ± 19.44%, 6.78 ± 4.96%, and 0.00 ± 13.66% against influenza viruses A and B. It was. Lamivudine, used as a hepatitis B virus inhibitor, did not show inhibitory effects against influenza viruses A and B at 7.44 ± 2.84% and 0.99 ± 11.41% (Table 1).

Plant Extracts against Influenza Virus Antiviral activity  analysis

As a result of analyzing the proliferation inhibitory activity against influenza virus A and B at the concentration of 50 ug / ml, three kinds of plant extracts were 67.10 ± 10.51% and 53.07 ± 5.42 for both influenza virus type A and B. % Showed significant inhibitory activity against the influenza virus type A and B, 42.44 ± 7.04% and 70.32 ± 18.98% against the influenza virus type A and B. Influenza virus type B and B. It showed a more powerful inhibitory effect. Oregano extract exhibited 0.00 ± 7.79%, 0.46 ± 9.95%, 3.81 ± 8.43%, and 108.88 ± 0.97% of inhibitory activity against influenza virus A at concentrations of 0.1, 1, 10, and 100 ug / ml. Influenza virus type A activity was completely inhibited. When banaba (50ug / ml), country (50ug / ml), oregano (100ug / ml) extracts were administered to the cells, the cell viability was 86.16 ± 4.80%, 85.31 ± 19.48%, 100.91%, which was very low for cell proliferation. There was no impact or no impact.

Therefore, in the present invention, it was found that the water-soluble extracts, the extracts of the barberry, and the oregano extracts had new inhibitory effects against influenza virus, and showed an excellent influenza virus inhibitory effect compared to the efficacy of amantadine used as an antiviral agent. Plant extracts of the species were found to have industrial useful value.

The composition comprising the extract of barnabas, acid, oregano or a combination thereof of the present invention can effectively prevent and treat influenza virus infection, which is a virus that causes respiratory diseases such as colds, and has less toxicity and side effects.

Claims (8)

An anti-influenza virus composition comprising a plant extract selected from at least one of banaba, country of origin and oregano.  The composition of claim 1 wherein the Banaba extract is a water extract.  The composition of claim 1, wherein the acid extract is an alcohol extract.  The composition of claim 1 wherein the oregano extract is an alcohol extract. The composition of claim 1, wherein the influenza virus is influenza A or B virus. A method of preventing or treating an influenza virus infection disease by administering the composition of claim 1 to an animal other than a human. 7. The method of claim 6, wherein the influenza virus is type A or type B. The method of claim 6, wherein the influenza virus infection disease is sinusitis, asthma, otitis media, cystic fibroma, bronchitis, pneumonia or diarrhea.